Last reviewed · How we verify
TIV
TIV is a trivalent inactivated influenza vaccine that stimulates immune response against three strains of influenza virus.
TIV is a trivalent inactivated influenza vaccine that stimulates immune response against three strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | TIV |
|---|---|
| Also known as | Trivalent Influenza Vaccines, Fluviral, Fluzone® TIV, 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine, Trivalent Inactivated Vaccine |
| Sponsor | Folia Biotech Inc. |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
TIV contains inactivated (killed) virus particles from three influenza strains (typically two A strains and one B strain) that trigger both humoral and cellular immune responses. The vaccine prepares the immune system to recognize and neutralize circulating influenza viruses, reducing infection risk and severity. Annual reformulation addresses evolving circulating strains.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- Post-exposure Influenza Prophylaxis (PHASE3)
- Opioid, HIV and Immune System (PHASE4)
- Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
- Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge
- Influenza Human Challenge Model (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIV CI brief — competitive landscape report
- TIV updates RSS · CI watch RSS
- Folia Biotech Inc. portfolio CI